Home > Oncology > SABCS 2021 > HR-positive/HER2-negative Breast Cancer > ctDNA is prognostic and predictive for response to ribociclib plus letrozole

ctDNA is prognostic and predictive for response to ribociclib plus letrozole

Presented By
Dr Giampaolo Bianchini, San Raffaele Scientific Institute, Italy
Conference
SABCS 2021
Trial
Phase 3, BioItaLEE
Pre-treatment circulating tumour DNA (ctDNA) and early dynamics of ctDNA represent promising prognostic and predictive biomarkers in patients with hormone receptor (HR)-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole in the first line. Patients with HR-positive/HER2-negative metastatic breast cancer benefit from treatment with ribociclib plus letrozole, the MONALEESA trials showed [1-3]. However, data on predictive biomarkers for response are limited and inconclusive. The aim of the phase 3 BioItaLEE trial (NCT03439046) was to assess the prognostic and predictive role of baseline and dynamic ctDNA in patients with HR-positive/HER2-negative advanced breast cancer treated in the first line with ribociclib plus letrozole. Dr Giampaolo Bianchini (San Raffaele Scientific Institute, It...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on